Michael J. Seckl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael J. Seckl has a total of 622 co-authors. Here are the top co-authors by number of shared publications:
- Olivier E. Pardo
Division of Cancer, Department of Surgery & Cancer, Faculty of Medicine, Imperial College London, London W12 0NN, UK
18 shared publications - Philip Savage
Department of Oncology, Brighton and Sussex University Hospitals, Brighton, UK
18 shared publications - Neil James Sebire
Great Ormond Street Institute of Child Health, University College London, London, UK
17 shared publications Baljeet Kaur
Department of Histopathology, Charing Cross Hospital, London, United Kingdom
14 shared publications- Rosemary Ann Fisher
Department of Surgery and Cancer, Imperial College London, Charing Cross Hospital, London
13 shared publications Dee Short
Department of Medical Oncology, Charing Cross Hospital Campus of Imperial College London, London, UK
12 shared publications
Latest Publications
- 20 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (18) , 1720-1729
Malignant Adult Ovarian Germ Cell Tumors: An International Multicenter Study to Identify Relevant Prognostic Risk Factors for Stage IC and Beyond
PURPOSE: Malignant ovarian germ cell tumors (MOGCTs) are rare, aggressive malignancies predominantly affecting young women. Unlike testicular germ cell tumors, prognostic factors are poorly understood, with small studies suggesting advanced stage as an adverse factor. Here, we examine a large international series to identify relevant prognostic factors. METHODS: We analyzed data from 254 patients with International Federation of Gynecology and Obstetrics stage IC-IV MOGCT, requiring surgery and chemotherapy between 1971 and 2018 at two UK and the Multicenter Italian Trials in Ovarian Cancer centers. RESULTS: The median age was 27 years (IQR, 21-31). Initial treatment was surgery in 87.8% of patients (50.4% fertility sparing, 37.4% nonsparing) or neoadjuvant chemotherapy. Most underwent BEP or POMB/ACE chemotherapy, with 32.5% receiving high-dose chemotherapy (HDCT) at relapse. First-line treatment resulted in a complete response in 84.6% (n = 215) and partial response or stable disease in 7.9% (n = 20), while 4.7% (n = 12) progressed. Overall, 37 patients (14.6%) died of disease. Ten-year progression-free survival and cancer-specific survival (CSS) was 82.8% (95% CI, 77.2 to 87.2) and 83.2% (95% CI, 77.3 to 87.7), respectively. CSS for stage IV disease was 79.4% (95% CI, 69.5 to 86.4). Age ≥35 years (hazard ratio [HR], 2.8 [95% CI, 1.5 to 5.4]; P = .003), stage III/IV disease (HR, 1.4 [95% CI, 1,0.2 to 1.9]; P = .035), and nondysgerminoma histology (HR, 7.3 [95% CI, 1.9 to 64.8]; P = .01) had worse CSS on multivariable analysis. By contrast, CSS of immature grade 2/3 MOGCT mirrored dysgerminomas. HDCT appeared to improve survival in first but not later relapses. CONCLUSION: Advanced stage (III/IV), age >35 years, and nondysgerminoma (excluding grade 2/3 immature teratomas) are adverse prognostic factors. Stage IV disease can achieve 80% long-term survival rates, and HDCT improves survival in first but not second relapse.
- 20 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (18) , 1720-1729
Malignant Adult Ovarian Germ Cell Tumors: An International Multicenter Study to Identify Relevant Prognostic Risk Factors for Stage IC and Beyond
PURPOSE: Malignant ovarian germ cell tumors (MOGCTs) are rare, aggressive malignancies predominantly affecting young women. Unlike testicular germ cell tumors, prognostic factors are poorly understood, with small studies suggesting advanced stage as an adverse factor. Here, we examine a large international series to identify relevant prognostic factors. METHODS: We analyzed data from 254 patients with International Federation of Gynecology and Obstetrics stage IC-IV MOGCT, requiring surgery and chemotherapy between 1971 and 2018 at two UK and the Multicenter Italian Trials in Ovarian Cancer centers. RESULTS: The median age was 27 years (IQR, 21-31). Initial treatment was surgery in 87.8% of patients (50.4% fertility sparing, 37.4% nonsparing) or neoadjuvant chemotherapy. Most underwent BEP or POMB/ACE chemotherapy, with 32.5% receiving high-dose chemotherapy (HDCT) at relapse. First-line treatment resulted in a complete response in 84.6% (n = 215) and partial response or stable disease in 7.9% (n = 20), while 4.7% (n = 12) progressed. Overall, 37 patients (14.6%) died of disease. Ten-year progression-free survival and cancer-specific survival (CSS) was 82.8% (95% CI, 77.2 to 87.2) and 83.2% (95% CI, 77.3 to 87.7), respectively. CSS for stage IV disease was 79.4% (95% CI, 69.5 to 86.4). Age ≥35 years (hazard ratio [HR], 2.8 [95% CI, 1.5 to 5.4]; P = .003), stage III/IV disease (HR, 1.4 [95% CI, 1,0.2 to 1.9]; P = .035), and nondysgerminoma histology (HR, 7.3 [95% CI, 1.9 to 64.8]; P = .01) had worse CSS on multivariable analysis. By contrast, CSS of immature grade 2/3 MOGCT mirrored dysgerminomas. HDCT appeared to improve survival in first but not later relapses. CONCLUSION: Advanced stage (III/IV), age >35 years, and nondysgerminoma (excluding grade 2/3 immature teratomas) are adverse prognostic factors. Stage IV disease can achieve 80% long-term survival rates, and HDCT improves survival in first but not second relapse.
- Open Access
- 28 May 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 135 (5) , 708-716
Depth of response to primary POMB/ACE chemotherapy predicts survival in poor prognosis germ-cell tumours
Background: Most chemotherapy regimens for poor-risk non-seminomatous germ cell tumours (PRGCT) deliver a fixed number of cycles; the role of variable treatment duration aiming for maximal response is unknown. Since the 1970s, we have utilised POMB/ACE chemotherapy for PRGCT, treating until marker normalisation. From mid-1990s, treatment was limited to 7 cycles. We describe outcomes with POMB/ACE for PRCGT, evaluating the association between treatment duration and survival. Methods: We conducted a retrospective cohort study across two UK tertiary cancer centres, identifying patients treated between 1978–2013. Complete response was defined based on normalisation of elevated tumour markers, absence of viable cancer in resection material and resolution of radiological abnormalities. Regression techniques were used to investigate the relationship between therapy duration and outcomes. Results: 132 PRGCT patients completed POMB/ACE with 69.7% ( n = 92) alive at 5 years. Number of cycles delivered significantly correlated with recurrence free survival (HR 0.52; 95% CI 0.38–0.71; p < 0.001) and complete biochemical response (OR 1.27; 95% CI 1.10–1.49; p = 0.0018). POMB/ACE discontinuation amongst patients with responding but not normalised tumour markers was associated with worse survival. Study limitations include the retrospective design. Conclusion: POMB/ACE is highly active for PRGCT. Treatment until maximal biochemical response is associated with superior survival outcomes and warrants further exploration.
- 28 May 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 135 (5) , 708-716
Open AccessDepth of response to primary POMB/ACE chemotherapy predicts survival in poor prognosis germ-cell tumours
Background: Most chemotherapy regimens for poor-risk non-seminomatous germ cell tumours (PRGCT) deliver a fixed number of cycles; the role of variable treatment duration aiming for maximal response is unknown. Since the 1970s, we have utilised POMB/ACE chemotherapy for PRGCT, treating until marker normalisation. From mid-1990s, treatment was limited to 7 cycles. We describe outcomes with POMB/ACE for PRCGT, evaluating the association between treatment duration and survival. Methods: We conducted a retrospective cohort study across two UK tertiary cancer centres, identifying patients treated between 1978–2013. Complete response was defined based on normalisation of elevated tumour markers, absence of viable cancer in resection material and resolution of radiological abnormalities. Regression techniques were used to investigate the relationship between therapy duration and outcomes. Results: 132 PRGCT patients completed POMB/ACE with 69.7% ( n = 92) alive at 5 years. Number of cycles delivered significantly correlated with recurrence free survival (HR 0.52; 95% CI 0.38–0.71; p < 0.001) and complete biochemical response (OR 1.27; 95% CI 1.10–1.49; p = 0.0018). POMB/ACE discontinuation amongst patients with responding but not normalised tumour markers was associated with worse survival. Study limitations include the retrospective design. Conclusion: POMB/ACE is highly active for PRGCT. Treatment until maximal biochemical response is associated with superior survival outcomes and warrants further exploration.
- Open Access
- 6 January 2026
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 50 (4) , 435-447
Primary Uterine Nongestational Placental Site Trophoblastic Tumor as a Distinct Entity
Uterine placental site trophoblastic tumors (PSTTs) are rare trophoblastic neoplasms, presumed to be of gestational origin. Herein, using a comprehensive morphologic, immunohistochemical, and molecular approach, we describe 5 cases of primary uterine nongestational PSTTs. The median age at presentation was 32 years (range 25 to 45). All tumors were initially expected to be of gestational origin as all were located in the uterus and all patients had a history of pregnancy (5/5, 100%). The median size of the primary uterine tumors was 6.3 cm (range 4.8 to 7.5). Three patients (3/5, 60%) had metastatic disease at presentation or revealed during initial workup (1/5 [20%] patients with lymph node metastasis only and 2/5 [40%] with distant metastases). All tumors showed similar histopathologic and immunohistochemical features to those of gestational PSTTs. The tumor cells expressed hPL in 5/5 (100%) tumors, hCG in 5/5 (100%; focal in all tumors), and GATA3 in 5/5 (100%). However, short tandem repeat (STR) genotyping did not identify any nonpatient alleles in the tumors, indicating a nongestational origin. The median progression-free survival was 18 months (range: 0 to 85) and 2/5 (40%) patients died from disease, highlighting the potential poor prognosis of this nongestational tumor. Thus, in the same way as gestational and nongestational choriocarcinomas are recognized as different entities, nongestational PSTTs could be viewed as a distinct entity from their gestational counterparts, although further investigation and more cases are needed. Furthermore, we propose recommendations for diagnosing and staging of nongestational PSTTs to improve patient stratification and management.
- 6 January 2026
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 50 (4) , 435-447
Open AccessPrimary Uterine Nongestational Placental Site Trophoblastic Tumor as a Distinct Entity
Uterine placental site trophoblastic tumors (PSTTs) are rare trophoblastic neoplasms, presumed to be of gestational origin. Herein, using a comprehensive morphologic, immunohistochemical, and molecular approach, we describe 5 cases of primary uterine nongestational PSTTs. The median age at presentation was 32 years (range 25 to 45). All tumors were initially expected to be of gestational origin as all were located in the uterus and all patients had a history of pregnancy (5/5, 100%). The median size of the primary uterine tumors was 6.3 cm (range 4.8 to 7.5). Three patients (3/5, 60%) had metastatic disease at presentation or revealed during initial workup (1/5 [20%] patients with lymph node metastasis only and 2/5 [40%] with distant metastases). All tumors showed similar histopathologic and immunohistochemical features to those of gestational PSTTs. The tumor cells expressed hPL in 5/5 (100%) tumors, hCG in 5/5 (100%; focal in all tumors), and GATA3 in 5/5 (100%). However, short tandem repeat (STR) genotyping did not identify any nonpatient alleles in the tumors, indicating a nongestational origin. The median progression-free survival was 18 months (range: 0 to 85) and 2/5 (40%) patients died from disease, highlighting the potential poor prognosis of this nongestational tumor. Thus, in the same way as gestational and nongestational choriocarcinomas are recognized as different entities, nongestational PSTTs could be viewed as a distinct entity from their gestational counterparts, although further investigation and more cases are needed. Furthermore, we propose recommendations for diagnosing and staging of nongestational PSTTs to improve patient stratification and management.
- 6 August 2025
- Published by Elsevier in Annals of Oncology
- Vol. 36 (10) , 1111-1112
Current and future treatments for low-risk gestational trophoblastic neoplasia
- 6 August 2025
- Published by Elsevier in Annals of Oncology
- Vol. 36 (10) , 1111-1112
Current and future treatments for low-risk gestational trophoblastic neoplasia
- Top Cited Papers
- 20 June 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (18) , 2119-2128
Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the European Organisation for the Treatment of Trophoblastic Disease (EOTTD)–European Society of Gynaecologic Oncology (ESGO)–Gynecologic Cancer InterGroup (GCIG)–International Society for the Study of Trophoblastic Diseases (ISSTD)
Gestational trophoblastic diseases (GTDs) are a group of pregnancy-related premalignant and malignant diseases with generally a favorable prognosis when treated adequately. Many different treatment protocols exist worldwide. To our knowledge, this is the first set of global consensus-based guidelines for GTD. Four international organizations (European Organisation for the Treatment of Trophoblastic Diseases, European Society of Gynecologic Oncology, Gynecologic Cancer Intergroup, and International Society for the Study of Trophoblastic Diseases) delegated 53 expert GTD clinicians from 31 countries who formulated nine consensus-based definitions and the minimum criteria required to be a GTD center. Furthermore, 18 flow diagrams were developed to diagnose, treat, and follow up all forms of primary or recurrent GTD. The definitions and flow diagrams were drafted and adapted in consecutive (online) meetings until consensus was reached followed by an external review process. Here, the final guidelines are presented together with the available supporting evidence from the literature.
- 20 June 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (18) , 2119-2128
Top Cited PapersPractical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the European Organisation for the Treatment of Trophoblastic Disease (EOTTD)–European Society of Gynaecologic Oncology (ESGO)–Gynecologic Cancer InterGroup (GCIG)–International Society for the Study of Trophoblastic Diseases (ISSTD)
Gestational trophoblastic diseases (GTDs) are a group of pregnancy-related premalignant and malignant diseases with generally a favorable prognosis when treated adequately. Many different treatment protocols exist worldwide. To our knowledge, this is the first set of global consensus-based guidelines for GTD. Four international organizations (European Organisation for the Treatment of Trophoblastic Diseases, European Society of Gynecologic Oncology, Gynecologic Cancer Intergroup, and International Society for the Study of Trophoblastic Diseases) delegated 53 expert GTD clinicians from 31 countries who formulated nine consensus-based definitions and the minimum criteria required to be a GTD center. Furthermore, 18 flow diagrams were developed to diagnose, treat, and follow up all forms of primary or recurrent GTD. The definitions and flow diagrams were drafted and adapted in consecutive (online) meetings until consensus was reached followed by an external review process. Here, the final guidelines are presented together with the available supporting evidence from the literature.
- Open Access
- 23 April 2025
- Published by BMJ in BMJ Medicine
- Vol. 4 (1) , e001017
Monitoring complete hydatidiform molar pregnancies after normalisation of human chorionic gonadotrophin: national retrospective population study
Objective: To provide evidence for a reduced surveillance protocol to detect gestational trophoblastic neoplasia after normalisation of human chorionic gonadotrophin (hCG) levels following uterine evacuation of a complete hydatidiform mole. Design: National retrospective population study Setting: Two UK Trophoblastic Disease Treatment Centres (Sheffield and London), 1 January 1980 to 30 November 2020. Participants: 17 424 patients with hCG normalisation after evacuation of their complete hydatidiform mole were included. Complete hydatidiform moles were verified by centralised pathological review. Patients were excluded if lost to follow-up or required treatment before normalisation of hCG levels. Main outcome measures: Incidence and clinical presentation of gestational trophoblastic neoplasia after normalisation of hCG levels following uterine evacuation of a complete hydatidiform mole. Results: Of 17 424 patients whose hCG normalised after complete hydatidiform mole evacuation, 99.8% (n=17 393 of 17 424) did not subsequently develop gestational trophoblastic neoplasia. The overall risk of gestational trophoblastic neoplasia after previous normalisation of hCG levels was 0.2% (n=31 of 17 424 patients). The risk of developing gestational trophoblastic neoplasia after uterine evacuation was substantially lower if hCG levels returned to normal in v 0.22%, 0.15% to 0.31%), with a posterior relative risk of 0.25 (0.06 to 0.72). Most patients who developed gestational trophoblastic neoplasia (71.0%, n=22 of 31) had received a diagnosis after the current six month surveillance protocol. The cumulative risk of developing gestational trophoblastic neoplasia in patients whose hCG levels normalised early increased minimally with time. If a patient had normal hCG levels in <56 days, a clinically relevant time point, the risk of developing gestational trophoblastic neoplasia was small (0.04%, about 1 in 2619 patients) at 39 months after normalisation. The equivalent risk for a patient who had normal hCG levels in ≥56 days was 0.16% (about 1 in 642 patients). All 31 women who developed gestational trophoblastic neoplasia achieved sustained remission after subsequent treatment. Conclusions: The findings of the study indicate that surveillance protocols could safely change to one confirmatory normal hCG value for patients whose hCG levels return to normal in <56 days of evacuation of a complete hydatidiform mole. Patients whose hCG levels return to normal in ≥56 days should be counselled on the remaining risk of gestational trophoblastic neoplasia over time to help decide the length of subsequent follow-up.
- 23 April 2025
- Published by BMJ in BMJ Medicine
- Vol. 4 (1) , e001017
Open AccessMonitoring complete hydatidiform molar pregnancies after normalisation of human chorionic gonadotrophin: national retrospective population study
Objective: To provide evidence for a reduced surveillance protocol to detect gestational trophoblastic neoplasia after normalisation of human chorionic gonadotrophin (hCG) levels following uterine evacuation of a complete hydatidiform mole. Design: National retrospective population study Setting: Two UK Trophoblastic Disease Treatment Centres (Sheffield and London), 1 January 1980 to 30 November 2020. Participants: 17 424 patients with hCG normalisation after evacuation of their complete hydatidiform mole were included. Complete hydatidiform moles were verified by centralised pathological review. Patients were excluded if lost to follow-up or required treatment before normalisation of hCG levels. Main outcome measures: Incidence and clinical presentation of gestational trophoblastic neoplasia after normalisation of hCG levels following uterine evacuation of a complete hydatidiform mole. Results: Of 17 424 patients whose hCG normalised after complete hydatidiform mole evacuation, 99.8% (n=17 393 of 17 424) did not subsequently develop gestational trophoblastic neoplasia. The overall risk of gestational trophoblastic neoplasia after previous normalisation of hCG levels was 0.2% (n=31 of 17 424 patients). The risk of developing gestational trophoblastic neoplasia after uterine evacuation was substantially lower if hCG levels returned to normal in v 0.22%, 0.15% to 0.31%), with a posterior relative risk of 0.25 (0.06 to 0.72). Most patients who developed gestational trophoblastic neoplasia (71.0%, n=22 of 31) had received a diagnosis after the current six month surveillance protocol. The cumulative risk of developing gestational trophoblastic neoplasia in patients whose hCG levels normalised early increased minimally with time. If a patient had normal hCG levels in <56 days, a clinically relevant time point, the risk of developing gestational trophoblastic neoplasia was small (0.04%, about 1 in 2619 patients) at 39 months after normalisation. The equivalent risk for a patient who had normal hCG levels in ≥56 days was 0.16% (about 1 in 642 patients). All 31 women who developed gestational trophoblastic neoplasia achieved sustained remission after subsequent treatment. Conclusions: The findings of the study indicate that surveillance protocols could safely change to one confirmatory normal hCG value for patients whose hCG levels return to normal in <56 days of evacuation of a complete hydatidiform mole. Patients whose hCG levels return to normal in ≥56 days should be counselled on the remaining risk of gestational trophoblastic neoplasia over time to help decide the length of subsequent follow-up.
- 29 January 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (3) , 101670
Controversies in malignant ovarian germ cell tumors
- 29 January 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (3) , 101670
Controversies in malignant ovarian germ cell tumors